112 related articles for article (PubMed ID: 7232826)
1. Therapeutic effects of BM 12,531 (Prop. INN azimexon).
Bicker U
Recent Results Cancer Res; 1980; 75():147-52. PubMed ID: 7232826
[TBL] [Abstract][Full Text] [Related]
2. Reduction of acute toxicity of cyclophosphamide and X-rays by the new immunomodulating compound BM 12.531.
Bicker U; Friedberg KD; Hebold G; Mengel K
Experientia; 1979 Oct; 35(10):1361-3. PubMed ID: 499423
[TBL] [Abstract][Full Text] [Related]
3. The effect of BM 12.531 (azimexon) on natural killer cell activity in myeloma patients.
Peter HH; Dziuba-Traber H; Boerner D
Eur J Cancer Clin Oncol; 1984 Mar; 20(3):353-9. PubMed ID: 6368246
[TBL] [Abstract][Full Text] [Related]
4. Animal experiments on the compensation of the immunosuppressive action of cyclophosphamide by 2-[-2-cyanaziridinyl-(1)-]-2-[-2-carbamoylaziridinyl-(1)]-propane BM 12 531.
Bicker U; Hebold G; Ziegler AE; Maus W
Exp Pathol (Jena); 1978; 15(1):49-62. PubMed ID: 346364
[TBL] [Abstract][Full Text] [Related]
5. Influence of the immunostimulating compound azimexone (2-[2-Cyanaziridinyl-(1)]-2-[2-carbamoylaziridinyl-(1)]-propane) on the number of metastases in the Lewis lung carcinoma in mice.
Probst E; Maus W; Bicker U
Exp Pathol; 1981; 19(1):15-8. PubMed ID: 7262270
[No Abstract] [Full Text] [Related]
6. [Biological effects of leakadin].
Garin AM; Lichinitser MR; Dmitrieva NV; Rubtsov BI; Leneva NV
Vopr Onkol; 1988; 34(2):192-6. PubMed ID: 2964757
[TBL] [Abstract][Full Text] [Related]
7. Immunorestoration of anergic cancer patients by azimexon.
Goutner A; Nasrat F; Bonardelle D; Rameau G
Recent Results Cancer Res; 1980; 75():47-52. PubMed ID: 7232839
[TBL] [Abstract][Full Text] [Related]
8. Three new agents for immunotherapy trials: azimexon, bestatin, and tuftsin.
Mathé G; Florentin I; Bruley-Rosset M; Goutner A; Serrou B
Recent Results Cancer Res; 1982; 80():331-3. PubMed ID: 6977171
[No Abstract] [Full Text] [Related]
9. Antitumour activity of some cyclophosphazenes.
Labarre JF; Faucher JP; Levy G; Sournies F; Cros S; François G
Eur J Cancer (1965); 1979 May; 15(5):637-43. PubMed ID: 510331
[No Abstract] [Full Text] [Related]
10. Effect of the immunomodulant 2-cyanaziridine derivative BM 41.332 on adjuvant arthritis in the rat.
Bicker U
Arzneimittelforschung; 1982; 32(7):746-52. PubMed ID: 6889876
[TBL] [Abstract][Full Text] [Related]
11. Investigations in mice on the potentiation of resistance to infections by a new immunostimulant compound.
Bicker U; Ziegler AE; Hebold G
J Infect Dis; 1979 Apr; 139(4):389-95. PubMed ID: 374647
[TBL] [Abstract][Full Text] [Related]
12. Isomer-dependent cytostatic activity of bis(1-aziridinyl)cyclophosphazenes.
van der Huizen AA; Wilting T; van de Grampel JC; Lelieveld P; van der Meer-Kalverkamp A; Lamberts HB; Mulder NH
J Med Chem; 1986 Aug; 29(8):1341-5. PubMed ID: 3735303
[TBL] [Abstract][Full Text] [Related]
13. The immunomodulatory effect on BM 12.531 (azimexon) on normal or tumored mice: in vitro and in vivo studies.
Stylos WA; Chirigos MA; Papademetriou V; Lauer L
J Immunopharmacol; 1980; 2(1):113-32. PubMed ID: 7452003
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of intravenous azimexon therapy in human cancer.
Patt YZ; Hersh EM; Reuben J; Claghorn L; Mavligit G
J Biol Response Mod; 1986 Aug; 5(4):313-8. PubMed ID: 2874196
[TBL] [Abstract][Full Text] [Related]
15. Influence of cyclophosphamide (Endoxan) and azimexone (BM 12.531), 2-[2-Cyanaziridinyl-(1)]-2-[2-carbamoylaziridinyl-(1)]-propane, on the bone marrow cells of mice.
Adam M; Ernst H; Bicker U
Exp Pathol; 1981; 19(1):1-14. PubMed ID: 7262269
[No Abstract] [Full Text] [Related]
16. Structural studies of immunomodulators. Part 2: Crystal structure and conformation of azimexon (BM 12.531) an immunostimulant and an anti-tumor drug.
Srikrishnan T
Anticancer Drug Des; 1990 May; 5(2):213-20. PubMed ID: 2357266
[TBL] [Abstract][Full Text] [Related]
17. The antineoplastic activity of hexaziridinocyclotriphosphazene (Myko 63) in murine tumors.
Malfiore C; Marmonti L; Filippeschi S; Labarre JF; Spreafico F
Anticancer Res; 1983; 3(6):425-9. PubMed ID: 6230986
[TBL] [Abstract][Full Text] [Related]
18. Increased lifespan using the priming dose schedule design in carbazilquinone (NSC-134679) treatment of mouse leukemia L1210.
Straus MJ; Goldin A
Cancer Chemother Rep; 1972 Feb; 56(1):19-23. PubMed ID: 5030804
[No Abstract] [Full Text] [Related]
19. Reduction of the immunosuppressive action of chemotherapeutics in patients with mammary carcinoma by Azimexon.
Kreienberg R; Boerner D; Melchert F; Lemmel EM
J Immunopharmacol; 1983; 5(1-2):49-64. PubMed ID: 6606686
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulation by the new synthetic compound BM 12.531, 2-[2-cyanaziridinyl-(1)]-[2-carbamoylaziridinyl-(1)]-propane (azimexone).
Luckenbach GA; Cortez-Campeao D; Modolell ML; Munder PG; Bicker U
Exp Pathol; 1981; 19(1):37-48. PubMed ID: 7262272
[No Abstract] [Full Text] [Related]
[Next] [New Search]
